Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

0 search results for

Suggestions within Pfizer.com

Press Release Archive

Press Releases

Year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Careers
Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

July 2024

07.17.2024
- Corporate
- Partnerships
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
07.11.2024
- Research and Pipeline
- Research
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
07.09.2024
- Corporate
- Leadership
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
07.01.2024
- Leadership
Cyrus Taraporevala Elected to Pfizer’s Board of Directors

June 2024

06.27.2024
- Vaccines
- Vaccines
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
06.26.2024
- Financial
- Finance
Pfizer Declares Third-Quarter 2024 Dividend
06.18.2024
- Financial
- Finance
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
06.14.2024
- Prescription Medicines
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
06.12.2024
- Research
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
06.03.2024
- Financial
- Finance
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
06.01.2024
- Prescription Medicines
- Research
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
06.01.2024
- Medicines
- Research
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Page 3
Page 4
Current page 5
Page 6
Page 7

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

Grant Seekers
Healthcare Professionals
Business to Business
Merchandise

Privacy Statement
Terms of Use
Contact Us

Glossary

© 2025 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube